
Outlook blindsided as FDA blocks wet AMD drug once again
Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.
Newsletters and Deep Dive digital magazine
Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.
Lilly has paused shipments of weight loss therapy Mounjaro to the UK to prevent stockpiling ahead of a price rise, but patients report shortages.
An attempt by the HHS to oust Susan Monarez as director of the CDC has run into a snag – she is refusing to step down.
RFK has declared the end of the COVID-19 emergency as the FDA issued approvals for the 2025 COVID shots in elderly and compromised patients only.
The field of neurotechnology is rapidly evolving, bringing together advances in neuroscience, engineering, materials science, and computing.
Editor's Picks
Newsletters and Deep Dive
digital magazine